You are currently using an unsupported browser which could affect the appearance and functionality of this website. Please consider upgrading to the latest version or using alternatives such as Mozilla Firefox, Google Chrome or Microsoft Edge.

This course is part of the RCOG Core Knowledge series.

Ovarian germ cell tumours (GCTs) may be benign or malignant. They constitute 15–20% of all ovarian tumours. They arise from primordial germ cells derived from the embryonal gonad. Malignant ovarian GCTs (MOGCTs) are rare, representing just 2–5% of all ovarian malignancies and 80% of the preadolescent malignant ovarian tumours. The yearly-adjusted incidence rate is 3.7/1 0000 Higher incidence rates are seen in African, South and East Asian and Hispanic patients compared with white Caucasian patients, suggesting some racial predilection. Increased incidence is seen in patients with gonadal dysgenesis, sexual immaturity and the presence of an abnormal karyotype. There is no identifiable genetic linkage for patients with MOGCTs, however chromosomal aberration of unknown clinical significant had been identified.

With multimodality treatment, including surgery and chemotherapy, most patients have an excellent prognosis and preservation of fertility is often possible.

When you have completed this course you will be able to:

  • explain the different types of germ cell tumours and their origin
  • discuss the incidence of these tumours and investigations required for this particular type of ovarian tumour
  • explain the appropriate treatment
  • counsel a woman and her family regarding the long-term effects of treatment on future fertility and the potential risks of the treatment itself
  • explain the long-term prognosis of treatment for a germ cell tumour.

Florian Drews MD MRCOG DFSRH (2016, 2022)
Mr Drews is a consultant Gynae-oncologist at the Royal Sussex County Hospital (Brighton). He holds dual certificate awarded by the Royal College as a specialist in obstetrics and gynaecology and as subspecialist in gynaecological oncology. He is also an accredited colposcopist with the British Society of Colposcopy. Mr Drews commenced his gynaecological oncology training Germany and completed his subspecialty training In Cardiff, Wales. He provides all aspect of surgical gynaeoncological care. He is known for his surgical expertise in advanced open abdominal and laparoscopic skills.

Radwa Hablase MRCOG MBBch (2022)
Radwa Hablase is a Speciality trainee ST5 at the Royal Sussex County Hospital (Brighton).

This course is intended to help clinicians gain core knowledge for O&G training and the MRCOG examinations. It can also be used by O&G consultants to refresh their knowledge of the area or for teaching.

Product Details:

Product Name Price
Germ cell tumours - 12 Month Access £50.40

Return to Catalogue